Liarozole NEW
| Price | $52 | $123 | $197 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-15 |
Product Details
| Product Name: Liarozole | CAS No.: 115575-11-6 |
| Purity: 99.38% | Supply Ability: 10g |
| Release date: 2026/07/15 |
Product Introduction
Bioactivity
| Name | Liarozole |
| Description | Liarozole (R75251 dihydrochloride) is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).Liarozole dihydrochloride is an imidazole derivative; it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders. |
| In vitro | Liarozole inhibits 17a-hydroxylase activity in bovine adrenal microsomes (IC50=0.15 μM) [1]. Liarozole has modest inhibitory activity on cholesterol synthesis in human hepatoma cells(IC50=5 μM)[1].Liarozole inhibits the metabolism of retinoic acid to more polar metabolites in hamster liver microsomes (IC50=2.2 μM), rat liver homogenate (IC50=0.14 μM), dunning prostate cancer homogenate (IC50=0.26 μM) and MCF-7 human breast cancer cells (almost complete block at 10μM) [1]. |
| Storage | Keep away from direct sunlight, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (178.13 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.48 mM), Sonication is recommended. |
| Keywords | SCID | RetinoidReceptor | Retinoid X receptors | Retinoid Receptor | Retinoic acid receptors | RAR/RXR | R-75251 Dihydrochloride | R75251 Dihydrochloride | R-75251 | R75251 | R 75251 Dihydrochloride | R 75251 | Ovariectomized | Mesenchymal | MCF-7 | Liarozole | Inhibitor | inhibit | Imidazole | Hydroxylation | Cytochrome P450 | CYPs | CYP450 |
| Inhibitors Related | Tebuconazole | Oxadiazon | Musk ketone | Naringin dihydrochalcone | Ipriflavone | Benzyl alcohol | Sudan IV | 2,4-Di-tert-butylphenol | Naringin | Dibenzothiophene | Clarithromycin | Memantine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Antioxidant Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2800.00 |
VIP3Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $52.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY